Aeterna Zentaris Inc. (AEZS): Price and Financial Metrics
GET POWR RATINGS... FREE!
AEZS POWR Grades
- Sentiment is the dimension where AEZS ranks best; there it ranks ahead of 87.98% of US stocks.
- AEZS's strongest trending metric is Value; it's been moving up over the last 56 days.
- AEZS's current lowest rank is in the Quality metric (where it is better than 5.8% of US stocks).
AEZS Stock Summary
- The ratio of debt to operating expenses for AETERNA ZENTARIS INC is higher than it is for about just 4.63% of US stocks.
- With a year-over-year growth in debt of -55.5%, AETERNA ZENTARIS INC's debt growth rate surpasses just 4.52% of about US stocks.
- In terms of volatility of its share price, AEZS is more volatile than 96.5% of stocks we're observing.
- Stocks that are quantitatively similar to AEZS, based on their financial statements, market capitalization, and price volatility, are MNDO, BGRY, MIRO, MTP, and IKT.
- AEZS's SEC filings can be seen here. And to visit AETERNA ZENTARIS INC's official web site, go to www.zentaris.com.
AEZS Valuation Summary
- In comparison to the median Healthcare stock, AEZS's EV/EBIT ratio is 74.38% lower, now standing at 2.6.
- AEZS's price/sales ratio has moved up 0.3 over the prior 243 months.
Below are key valuation metrics over time for AEZS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AEZS | 2023-01-30 | 2.8 | 0.4 | -1.4 | 2.6 |
| AEZS | 2023-01-27 | 2.7 | 0.4 | -1.3 | 2.7 |
| AEZS | 2023-01-26 | 2.7 | 0.4 | -1.3 | 2.7 |
| AEZS | 2023-01-25 | 2.7 | 0.4 | -1.4 | 2.7 |
| AEZS | 2023-01-24 | 2.7 | 0.4 | -1.3 | 2.7 |
| AEZS | 2023-01-23 | 2.8 | 0.4 | -1.4 | 2.6 |
AEZS Growth Metrics
- Its year over year net income to common stockholders growth rate is now at -30.25%.
- Its 3 year net cashflow from operations growth rate is now at 30.24%.
- Its 5 year revenue growth rate is now at 70.43%.
The table below shows AEZS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 6.628 | -12.669 | -13.462 |
| 2022-06-30 | 5.37 | -10.212 | -11.74 |
| 2022-06-30 | 5.37 | -10.212 | -11.74 |
| 2022-03-31 | 6.191 | -8.997 | -9.563 |
| 2021-12-31 | 5.26 | -8.581 | -8.368 |
| 2021-12-31 | 5.26 | -8.581 | -8.368 |
AEZS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AEZS has a Quality Grade of F, ranking ahead of 3.18% of graded US stocks.
- AEZS's asset turnover comes in at 0.128 -- ranking 241st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows AEZS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.128 | 0.366 | 4.492 |
| 2020-12-31 | 0.128 | 0.366 | 4.492 |
| 2019-12-31 | 0.024 | 0.229 | 2.567 |
| 2018-12-31 | 1.139 | 0.922 | -4.563 |
| 2018-12-31 | 1.139 | 0.922 | -4.563 |
| 2017-12-31 | 0.034 | 1.000 | 13.076 |
AEZS Stock Price Chart Interactive Chart >
AEZS Price/Volume Stats
| Current price | $3.72 | 52-week high | $10.99 |
| Prev. close | $3.76 | 52-week low | $2.89 |
| Day low | $3.72 | Volume | 19,698 |
| Day high | $3.90 | Avg. volume | 12,559 |
| 50-day MA | $3.60 | Dividend yield | N/A |
| 200-day MA | $4.56 | Market Cap | 18.06M |
Aeterna Zentaris Inc. (AEZS) Company Bio
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company was founded in 1991 and is based in Summerville, South Carolina.
Latest AEZS News From Around the Web
Below are the latest news stories about AETERNA ZENTARIS INC that investors may wish to consider to help them evaluate AEZS as an investment opportunity.
Aeterna Zentaris Shelves Early-Stage Vaccine Programs, Including COVID-19Aeterna Zentaris Inc (NASDAQ: AEZS ) has decided to streamline development programs by discontinuing its early-stage vaccine programs . The company worked on evaluating administration routes, dosing, and immunization scheme and conducted in-vivo immunology experiments with candidate strains expressing various antigens in relevant mice models. To date, the company has not been able to select a clinical development candidate for a COVID-19 … Full story available on Benzinga.com |
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming MilestonesAeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development pipeline, advancing towards go/no-go decision milestones at each stage to establish prioritization and drive momentumStrategic decision to streamline development programs by discontinuing the Company’s early-stage vaccine programs provides Aeterna Zentaris with an expected extended cas |
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19thJTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. |
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch EventLive video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 1 |
Aeterna Zentaris Reports Third Quarter 2022 Financial Results– Company ended the quarter with $ 53.8 million in cash |
AEZS Price Returns
| 1-mo | 15.53% |
| 3-mo | -7.23% |
| 6-mo | -25.15% |
| 1-year | -58.62% |
| 3-year | -85.69% |
| 5-year | -92.88% |
| YTD | 16.98% |
| 2022 | -64.20% |
| 2021 | -16.50% |
| 2020 | -53.24% |
| 2019 | -69.05% |
| 2018 | 24.58% |
Continue Researching AEZS
Want to see what other sources are saying about Aeterna Zentaris Inc's financials and stock price? Try the links below:Aeterna Zentaris Inc (AEZS) Stock Price | Nasdaq
Aeterna Zentaris Inc (AEZS) Stock Quote, History and News - Yahoo Finance
Aeterna Zentaris Inc (AEZS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...